München (ots) - Neue Doku-Serie über Kinderärzte und ihre kleinen Patienten - Vier Folgen ab Mittwoch, ...
European Survey to Gain Insight into Treatment-Experienced Patients' Perspectives on Living with HIV
Sydney, Australia (ots/PRNewswire) -
Recent launches of new protease inhibitors and the anticipated availability of new antiretroviral drug classes have increased the therapeutic options available to treatment-experienced HIV-positive patients, and made achieving an undetectable viral load a realistic goal for this patient population. With these treatment advances, it has become important to understand the unique needs and perspectives of treatment-experienced individuals, a growing population.
Coinciding with the annual conference of International AIDS Society (IAS) in Sydney, Australia, Boehringer Ingelheim announced the launch of the HIV TALK (Treatment, Attitudes, Life, Knowledge) survey, a project supported by the International AIDS Society, which will gain insight into treatment-experienced individuals' attitudes about HIV therapy and living with HIV, potential gaps in education and information, perceptions toward treatment and ways to improve patient-physician dialogue about HIV care.
The HIV TALK survey will be fielded to five hundred HIV-positive individuals who have undergone treatment with multiple antiretrovirals throughout France, Germany, Italy, Spain and the United Kingdom. These countries have the largest populations of HIV-positive individuals in Western Europe.
"Great strides in HIV research enable HIV-positive individuals to live longer, healthier lives. With these treatment advances, it is also important to understand treatment-experienced individuals' attitudes, outlooks, and the level of patient-physician dialogue. Through the HIV TALK survey, we hope to gain this valuable information and increase awareness of the needs of this growing patient population and the importance of patient-physician dialogue," said Juergen Rockstroh, M.D., professor of medicine, Universitat Bonn, Germany.(i)
Results are expected in October, 2007. For more information please visit www.ias.org/media.
Boehringer Ingelheim is a pharmaceutical company committed to the research and development of novel antiretroviral agents and to improving HIV therapy by providing physicians and patients with innovative antiretrovirals. For more information, please see www.boehringer-ingelheim.com/hiv.
The IAS is the world's leading independent association of HIV professionals, with over 10,000 members in 171 countries. The IAS was founded as a non-profit organisation in connection with the IV International AIDS Conference in Stockholm in 1988; primarily to decide on future venues of the series of International AIDS Conferences and to serve as a network for those working with HIV/AIDS. For more information, please visit http://www.ias2007.org/media
(i) UNAIDS/WHO: 2006 Report on the global AIDS epidemic
ots Originaltext: Boehringer Ingelheim
Im Internet recherchierbar: http://www.presseportal.ch
Lauren Graham, +1-212-537-8129, for Boehringer Ingelheim